Oramed Pharmaceuticals (Israel) Valuation

Oramed Pharmaceuticals recent Real Value cannot be determined due to lack of data. The prevailing price of Oramed Pharmaceuticals is 0.0. Based on Macroaxis valuation methodology, the company cannot be evaluated at this time. Macroaxis determines value of Oramed Pharmaceuticals from analyzing the company fundamentals such as Return On Equity of (66.70)%, Price to Book of 940.33X and Current Valuation of 216.77M as well as examining its technical indicators and Probability Of Bankruptcy. In general, we support investing in undervalued entities and to dispose of overvalued entities since at some point stocks prices and their ongoing real values will merge together.
Horizon     30 Days    Login   to change
Oramed Pharmaceuticals is considered to be number one stock in price to book category among related companies. It is considered to be number one stock in beta category among related companies . The ratio of Price to Book to Beta for Oramed Pharmaceuticals is about  803.70 
Follow Benchmarks with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
See also Your Equity Center. Please also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Search macroaxis.com